If you made any changes in Pure these will be visible here soon.

Research Output

2020
2019

Adjuvant radiotherapy for Merkel cell carcinoma: A systematic review and meta-analysis

Petrelli, F., Ghidini, A., Torchio, M., Prinzi, N., Trevisan, F., Dallera, P., De Stefani, A., Russo, A., Vitali, E., Bruschieri, L., Costanzo, A., Seghezzi, S., Ghidini, M., Varricchio, A., Cabiddu, M., Barni, S., de Braud, F. & Pusceddu, S., May 2019, In : Radiotherapy and Oncology. 134, p. 211-219 9 p.

Research output: Contribution to journalReview article

Open Access

Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: The ARMANI phase III trial

Di Bartolomeo, M., Niger, M., Morano, F., Corallo, S., Antista, M., Tamberi, S., Lonardi, S., Di Donato, S., Berardi, R., Scartozzi, M., Cardellino, G. G., Di Costanzo, F., Rimassa, L., Luporini, A. G., Longarini, R., Zaniboni, A., Bertolini, A., Tomasello, G., Pinotti, G., Scagliotti, G. & 19 others, Tortora, G., Bonetti, A., Spallanzani, A., Frassineti, G. L., Tassinari, D., Giuliani, F., Cinieri, S., Maiello, E., Verusio, C., Bracarda, S., Catalano, V., Basso, M., Ciuffreda, L., De Vita, F., Parra, H. S., Fornaro, L., Caporale, M., De Braud, F. & Pietrantonio, F., Mar 29 2019, In : BMC Cancer. 19, 1, 283.

Research output: Contribution to journalArticle

Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: The ARMANI phase III trial

Di Bartolomeo, M., Niger, M., Morano, F., Corallo, S., Antista, M., Tamberi, S., Lonardi, S., Di Donato, S., Berardi, R., Scartozzi, M., Cardellino, G. G., Di Costanzo, F., Rimassa, L., Luporini, A. G., Longarini, R., Zaniboni, A., Bertolini, A., Tomasello, G., Pinotti, G., Scagliotti, G. & 19 others, Tortora, G., Bonetti, A., Spallanzani, A., Frassineti, G. L., Tassinari, D., Giuliani, F., Cinieri, S., Maiello, E., Verusio, C., Bracarda, S., Catalano, V., Basso, M., Ciuffreda, L., De Vita, F., Parra, H. S., Fornaro, L., Caporale, M., De Braud, F. & Pietrantonio, F., Mar 29 2019, In : BMC Cancer. 19, 1, 283.

Research output: Contribution to journalArticle

Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: The ARMANI phase III trial

Di Bartolomeo, M., Niger, M., Morano, F., Corallo, S., Antista, M., Tamberi, S., Lonardi, S., Di Donato, S., Berardi, R., Scartozzi, M., Cardellino, G. G., Di Costanzo, F., Rimassa, L., Luporini, A. G., Longarini, R., Zaniboni, A., Bertolini, A., Tomasello, G., Pinotti, G., Scagliotti, G. & 19 others, Tortora, G., Bonetti, A., Spallanzani, A., Frassineti, G. L., Tassinari, D., Giuliani, F., Cinieri, S., Maiello, E., Verusio, C., Bracarda, S., Catalano, V., Basso, M., Ciuffreda, L., De Vita, F., Parra, H. S., Fornaro, L., Caporale, M., De Braud, F. & Pietrantonio, F., 2019, In : BMC Cancer. 19, 1

Research output: Contribution to journalArticle

Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: The ARMANI phase III trial

Di Bartolomeo, M., Niger, M., Morano, F., Corallo, S., Antista, M., Tamberi, S., Lonardi, S., Di Donato, S., Berardi, R., Scartozzi, M., Cardellino, G. G., Di Costanzo, F., Rimassa, L., Luporini, A. G., Longarini, R., Zaniboni, A., Bertolini, A., Tomasello, G., Pinotti, G., Scagliotti, G. & 19 others, Tortora, G., Bonetti, A., Spallanzani, A., Frassineti, G. L., Tassinari, D., Giuliani, F., Cinieri, S., Maiello, E., Verusio, C., Bracarda, S., Catalano, V., Basso, M., Ciuffreda, L., De Vita, F., Parra, H. S., Fornaro, L., Caporale, M., De Braud, F. & Pietrantonio, F., 2019, In : BMC Cancer. 19, 1

Research output: Contribution to journalArticle

Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: The ARMANI phase III trial

Di Bartolomeo, M., Niger, M., Morano, F., Corallo, S., Antista, M., Tamberi, S., Lonardi, S., Di Donato, S., Berardi, R., Scartozzi, M., Cardellino, G. G., Di Costanzo, F., Rimassa, L., Luporini, A. G., Longarini, R., Zaniboni, A., Bertolini, A., Tomasello, G., Pinotti, G., Scagliotti, G. & 19 others, Tortora, G., Bonetti, A., Spallanzani, A., Frassineti, G. L., Tassinari, D., Giuliani, F., Cinieri, S., Maiello, E., Verusio, C., Bracarda, S., Catalano, V., Basso, M., Ciuffreda, L., De Vita, F., Parra, H. S., Fornaro, L., Caporale, M., De Braud, F. & Pietrantonio, F., Mar 29 2019, In : BMC Cancer. 19, 1, p. 1-9 9 p.

Research output: Contribution to journalArticle

Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer

Galli, G., Triulzi, T., Proto, C., Signorelli, D., Imbimbo, M., Poggi, M., Fucà, G., Ganzinelli, M., Vitali, M., Palmieri, D., Tessari, A., de Braud, F., Garassino, M. C., Colombo, M. P. & Lo Russo, G., Jun 2019, In : Lung Cancer. 132, p. 72-78 7 p.

Research output: Contribution to journalArticle

Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer

Pietrantonio, F., Lobefaro, R., Antista, M., Lonardi, S., Raimondi, A., Morano, F., Mosconi, S., Rimassa, L., Murgioni, S., Sartore-Bianchi, A., Tomasello, G., Longarini, R., Farina, G., Petrelli, F., Gori, S., Randon, G., Corallo, S., Pagani, F., Guarini, V., Palermo, F. & 11 others, Martinetti, A., Macagno, M., Barault, L., Perrone, F., Tamborini, E., Milione, M., Di Nicolantonio, F., Di Maio, M., Fucà, G., Di Bartolomeo, M. & de Braud, F., Nov 18 2019, In : Clin. Cancer Res..

Research output: Contribution to journalArticle

Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer

Pietrantonio, F., Lobefaro, R., Antista, M., Lonardi, S., Raimondi, A., Morano, F., Mosconi, S., Rimassa, L., Murgioni, S., Sartore-Bianchi, A., Tomasello, G., Longarini, R., Farina, G., Petrelli, F., Gori, S., Randon, G., Corallo, S., Pagani, F., Guarini, V., Palermo, F. & 11 others, Martinetti, A., Macagno, M., Barault, L., Perrone, F., Tamborini, E., Milione, M., Di Nicolantonio, F., Di Maio, M., Fucà, G., Di Bartolomeo, M. & de Braud, F., Nov 18 2019, In : Clin. Cancer Res.. p. 1-27 27 p.

Research output: Contribution to journalArticle

Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy

Galli, G., Proto, C., Signorelli, D., Imbimbo, M., Ferrara, R., Prelaj, A., De Toma, A., Ganzinelli, M., Zilembo, N., De Braud, F., Garassino, M. C. & Lo Russo, G., Aug 2019, In : Future Oncology. 15, 23, p. 2743-2757 15 p.

Research output: Contribution to journalArticle

Collecting ducts carcinoma: An orphan disease. Literature overview and future perspectives

Pagani, F., Colecchia, M., Sepe, P., Apollonio, G., Claps, M., Verzoni, E., de Braud, F. & Procopio, G., Sep 2019, In : Cancer Treatment Reviews. 79, 101891.

Research output: Contribution to journalReview article

Open Access

Combination of Immunotherapy and Brain Radiotherapy in Metastatic Melanoma: A Retrospective Analysis

Galli, G., Cavalieri, S., Di Guardo, L., Cimminiello, C., Nichetti, F., Corti, F., Garcia, M. A., Pappalardi, B., Fallai, C., De Braud, F., Platania, M. & Del Vecchio, M., Apr 1 2019, In : Oncology Research and Treatment. 42, 4, p. 182-188 7 p.

Research output: Contribution to journalArticle

Comparative effectiveness of gemcitabine plus nab-paclitaxel and folfirinox in the first-line setting of metastatic pancreatic cancer: A systematic review and meta-analysis

Pusceddu, S., Ghidini, M., Torchio, M., Corti, F., Tomasello, G., Niger, M., Prinzi, N., Nichetti, F., Coinu, A., Bartolomeo, M. D., Cabiddu, M., Passalacqua, R., De Braud, F. & Petrelli, F., Apr 2019, In : Cancers. 11, 4, 484.

Research output: Contribution to journalArticle

Open Access

Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma

Mazzaferro, V., El-Rayes, B. F., Droz Dit Busset, M., Cotsoglou, C., Harris, W. P., Damjanov, N., Masi, G., Rimassa, L., Personeni, N., Braiteh, F., Zagonel, V., Papadopoulos, K. P., Hall, T., Wang, Y., Schwartz, B., Kazakin, J., Bhoori, S., de Braud, F. & Shaib, W. L., Jan 2019, In : British Journal of Cancer. 120, 2, p. 165-171 7 p.

Research output: Contribution to journalArticle

Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma

Mazzaferro, V., El-Rayes, B. F., Droz dit Busset, M., Cotsoglou, C., Harris, W. P., Damjanov, N., Masi, G., Rimassa, L., Personeni, N., Braiteh, F., Zagonel, V., Papadopoulos, K. P., Hall, T., Wang, Y., Schwartz, B., Kazakin, J., Bhoori, S., de Braud, F. & Shaib, W. L., 2019, In : British Journal of Cancer. 120, 2, p. 165-171 7 p.

Research output: Contribution to journalArticle

Developing a score system to predict therapeutic outcomes to anti-PD-1 immunotherapy in metastatic melanoma

Indini, A., Di Guardo, L., Cimminiello, C., Prisciandaro, M., Randon, G., De Braud, F. & Del Vecchio, M., Jan 1 2019, (Accepted/In press) In : Tumori.

Research output: Contribution to journalArticle

DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients

Del Re, M., Cinieri, S., Michelucci, A., Salvadori, S., Loupakis, F., Schirripa, M., Cremolini, C., Crucitta, S., Barbara, C., Di Leo, A., Latiano, T. P., Pietrantonio, F., Di Donato, S., Simi, P., Passardi, A., De Braud, F., Altavilla, G., Zamagni, C., Bordonaro, R., Butera, A. & 6 others, Maiello, E., Pinto, C., Falcone, A., Mazzotti, V., Morganti, R. & Danesi, R., Dec 2019, In : Pharmacogenomics Journal. 19, 6, p. 556-563 8 p.

Research output: Contribution to journalArticle

DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients

Del Re, M., Cinieri, S., Michelucci, A., Salvadori, S., Loupakis, F., Schirripa, M., Cremolini, C., Crucitta, S., Barbara, C., Di Leo, A., Latiano, T. P., Pietrantonio, F., Di Donato, S., Simi, P., Passardi, A., De Braud, F., Altavilla, G., Zamagni, C., Bordonaro, R., Butera, A. & 6 others, Maiello, E., Pinto, C., Falcone, A., Mazzotti, V., Morganti, R. & Danesi, R., Dec 2019, In : Pharmacogenomics Journal. 19, 6, p. 556-563 8 p.

Research output: Contribution to journalArticle

DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients

Del Re, M., Cinieri, S., Michelucci, A., Salvadori, S., Loupakis, F., Schirripa, M., Cremolini, C., Crucitta, S., Barbara, C., Di Leo, A., Latiano, T. P., Pietrantonio, F., Di Donato, S., Simi, P., Passardi, A., De Braud, F., Altavilla, G., Zamagni, C., Bordonaro, R., Butera, A. & 6 others, Maiello, E., Pinto, C., Falcone, A., Mazzotti, V., Morganti, R. & Danesi, R., Jan 1 2019, In : Pharmacogenomics Journal.

Research output: Contribution to journalArticle

DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients

Del Re, M., Cinieri, S., Michelucci, A., Salvadori, S., Loupakis, F., Schirripa, M., Cremolini, C., Crucitta, S., Barbara, C., Di Leo, A., Latiano, T. P., Pietrantonio, F., Di Donato, S., Simi, P., Passardi, A., De Braud, F., Altavilla, G., Zamagni, C., Bordonaro, R., Butera, A. & 6 others, Maiello, E., Pinto, C., Falcone, A., Mazzotti, V., Morganti, R. & Danesi, R., 2019, In : Pharmacogenomics Journal. 19, 6, p. 556-563 8 p.

Research output: Contribution to journalArticle

DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients

Del Re, M., Cinieri, S., Michelucci, A., Salvadori, S., Loupakis, F., Schirripa, M., Cremolini, C., Crucitta, S., Barbara, C., Di Leo, A., Latiano, T. P., Pietrantonio, F., Di Donato, S., Simi, P., Passardi, A., De Braud, F., Altavilla, G., Zamagni, C., Bordonaro, R., Butera, A. & 6 others, Maiello, E., Pinto, C., Falcone, A., Mazzotti, V., Morganti, R. & Danesi, R., Dec 1 2019, In : Pharmacogenomics. 19, 6, p. 556-563 8 p.

Research output: Contribution to journalArticle

Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer

Galli, G., De Toma, A., Pagani, F., Randon, G., Trevisan, B., Prelaj, A., Ferrara, R., Proto, C., Signorelli, D., Ganzinelli, M., Zilembo, N., de Braud, F., Garassino, M. C. & Lo Russo, G., Nov 2019, In : Lung Cancer. 137, p. 38-42 5 p.

Research output: Contribution to journalArticle

Entering the third decade of experience with octreotide LAR in neuroendocrine tumors: A review of current knowledge

Pusceddu, S., Prinzi, N., Raimondi, A., Corti, F., Buzzoni, R., Di Bartolomeo, M., Seregni, E., Maccauro, M., Coppa, J., Milione, M., Mazzaferro, V. & de Braud, F., Apr 1 2019, In : Tumori. 105, 2, p. 113-120 8 p.

Research output: Contribution to journalReview article

Epsilon: A prognostic score for immunotherapy in advanced non-small-cell lung cancer: A validation cohort

Prelaj, A., Ferrara, R., Rebuzzi, S. E., Proto, C., Signorelli, D., Galli, G., De Toma, A., Randon, G., Pagani, F., Viscardi, G., Brambilla, M., Trevisan, B., Ganzinelli, M., Martinetti, A., Gallucci, R., Di Mauro, R. M., Molino, G., Zilembo, N., Torri, V., de Braud, F. M. & 2 others, Garassino, M. C. & Lo Russo, G., Dec 2019, In : Cancers. 11, 12, 1954.

Research output: Contribution to journalArticle

Open Access

Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial

Vernieri, C., Signorelli, D., Galli, G., Ganzinelli, M., Moro, M., Fabbri, A., Tamborini, E., Marabese, M., Caiola, E., Broggini, M., Hollander, L., Gallucci, R., Vandoni, G., Gavazzi, C., Triulzi, T., Colombo, M. P., Rizzo, A. M., Corsetto, P. A., Pruneri, G., de Braud, F. & 3 others, Sozzi, G., Torri, V. & Garassino, M. C., May 2019, In : Clinical Lung Cancer. 20, 3, p. e413-e417

Research output: Contribution to journalArticle

Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma

Indini, A., Di Guardo, L., Cimminiello, C., Prisciandaro, M., Randon, G., De Braud, F. & Del Vecchio, M., Feb 13 2019, In : Journal of Cancer Research and Clinical Oncology. 145, 2, p. 511-521 11 p.

Research output: Contribution to journalArticle

Impact of dexamethasone-sparing regimens on delayed nausea caused by moderately or highly emetogenic chemotherapy: A meta-analysis of randomised evidence

Celio, L., Bonizzoni, E., Zattarin, E., Codega, P., De Braud, F. & Aapro, M., Dec 30 2019, In : BMC Cancer. 19, 1, 1268.

Research output: Contribution to journalArticle

Open Access
Open Access

Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs)

Vernieri, C., Pusceddu, S., Fucà, G., Indelicato, P., Centonze, G., Castagnoli, L., Ferrari, E., Ajazi, A., Pupa, S., Casola, S., Foiani, M., Mazzaferro, V., Pruneri, G., Milione, M. & de Braud, F., Apr 1 2019, In : International Journal of Cancer. 144, 7, p. 1704-1712 9 p.

Research output: Contribution to journalArticle

Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients?

Nichetti, F., Falvella, F. S., Miceli, R., Cheli, S., Gaetano, R., Fucà, G., Infante, G., Martinetti, A., Antoniotti, C., Falcone, A., Di Bartolomeo, M., Cremolini, C., de Braud, F. & Pietrantonio, F., 2019, In : Pharmacogenomics Journal. 19, 5, p. 465-472 8 p.

Research output: Contribution to journalArticle

Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients?

Nichetti, F., Falvella, F. S., Miceli, R., Cheli, S., Gaetano, R., Fucà, G., Infante, G., Martinetti, A., Antoniotti, C., Falcone, A., Di Bartolomeo, M., Cremolini, C., de Braud, F. & Pietrantonio, F., Oct 1 2019, In : Pharmacogenomics Journal. 19, 5, p. 465-472 8 p.

Research output: Contribution to journalArticle

Is there an interplay between immune checkpoint inhibitors, thromboprophylactic treatments and thromboembolic events? Mechanisms and impact in non-small cell lung cancer patients

Nichetti, F., Ligorio, F., Zattarin, E., Signorelli, D., Prelaj, A., Proto, C., Galli, G., Marra, A., Apollonio, G., Porcu, L., de Braud, F., Lo Russo, G., Ferrara, R. & Garassino, M. C., Dec 2019, In : Cancers. 12, 1, 67.

Research output: Contribution to journalArticle

Open Access

Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component

Moretto, R., Morano, F., Ongaro, E., Rossini, D., Pietrantonio, F., Casagrande, M., Antoniotti, C., Corallo, S., Marmorino, F., Cortiula, F., Nichetti, F., Borelli, B., Zucchelli, G., Boccaccino, A., Masi, G., de Braud, F., Falcone, A. & Cremolini, C., Jun 2019, In : Clinical Colorectal Cancer. 18, 2, p. 116-124 9 p.

Research output: Contribution to journalArticle

Maintenance Therapy with Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients with RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial

Pietrantonio, F., Morano, F., Corallo, S., Miceli, R., Lonardi, S., Raimondi, A., Cremolini, C., Rimassa, L., Bergamo, F., Sartore-Bianchi, A., Tampellini, M., Racca, P., Clavarezza, M., Berenato, R., Caporale, M., Antista, M., Niger, M., Smiroldo, V., Murialdo, R., Zaniboni, A. & 10 others, Adamo, V., Tomasello, G., Giordano, M., Petrelli, F., Longarini, R., Cinieri, S., Falcone, A., Zagonel, V., Di Bartolomeo, M. & De Braud, F., Jan 1 2019, In : JAMA oncology.

Research output: Contribution to journalArticle

Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial

Pietrantonio, F., Morano, F., Corallo, S., Miceli, R., Lonardi, S., Raimondi, A., Cremolini, C., Rimassa, L., Bergamo, F., Sartore-Bianchi, A., Tampellini, M., Racca, P., Clavarezza, M., Berenato, R., Caporale, M., Antista, M., Niger, M., Smiroldo, V., Murialdo, R., Zaniboni, A. & 10 others, Adamo, V., Tomasello, G., Giordano, M., Petrelli, F., Longarini, R., Cinieri, S., Falcone, A., Zagonel, V., Di Bartolomeo, M. & de Braud, F., Jul 3 2019, In : JAMA oncology.

Research output: Contribution to journalArticle

Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial

Pietrantonio, F., Morano, F., Corallo, S., Miceli, R., Lonardi, S., Raimondi, A., Cremolini, C., Rimassa, L., Bergamo, F., Sartore-Bianchi, A., Tampellini, M., Racca, P., Clavarezza, M., Berenato, R., Caporale, M., Antista, M., Niger, M., Smiroldo, V., Murialdo, R., Zaniboni, A. & 10 others, Adamo, V., Tomasello, G., Giordano, M., Petrelli, F., Longarini, R., Cinieri, S., Falcone, A., Zagonel, V., Di Bartolomeo, M. & de Braud, F., Jul 3 2019, In : JAMA oncology. 5, 9, p. 1268-1275 8 p.

Research output: Contribution to journalArticle

Metronomic Capecitabine With Cyclophosphamide Regimen in Unresectable or Relapsed Pseudomyxoma Peritonei

Raimondi, A., Corallo, S., Niger, M., Antista, M., Randon, G., Morano, F., Milione, M., Kusamura, S., Baratti, D., Guaglio, M., Cremolini, C., Marmorino, F., Di Bartolomeo, M., Deraco, M., De Braud, F. & Pietrantonio, F., Jun 2019, In : Clinical Colorectal Cancer. 18, 2, p. e179-e190

Research output: Contribution to journalArticle

Negative hyperselection of patients with RAS and BRAF wild-type metastatic colorectal cancer who received panitumumab-based maintenance therapy

Morano, F., Corallo, S., Lonardi, S., Raimondi, A., Cremolini, C., Rimassa, L., Murialdo, R., Zaniboni, A., Sartore-Bianchi, A., Tomasello, G., Racca, P., Clavarezza, M., Adamo, V., Perrone, F., Gloghini, A., Tamborini, E., Busico, A., Martinetti, A., Palermo, F., Loupakis, F. & 5 others, Milione, M., Fucà, G., Di Bartolomeo, M., De Braud, F. & Pietrantonio, F., 2019, In : Journal of Clinical Oncology. 37, 33, p. 3099-3110 12 p.

Research output: Contribution to journalArticle

Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy

Morano, F., Corallo, S., Lonardi, S., Raimondi, A., Cremolini, C., Rimassa, L., Murialdo, R., Zaniboni, A., Sartore-Bianchi, A., Tomasello, G., Racca, P., Clavarezza, M., Adamo, V., Perrone, F., Gloghini, A., Tamborini, E., Busico, A., Martinetti, A., Palermo, F., Loupakis, F. & 5 others, Milione, M., Fucà, G., Di Bartolomeo, M., de Braud, F. & Pietrantonio, F., Nov 20 2019, In : Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 37, 33, p. 3099-3110 12 p.

Research output: Contribution to journalArticle

Open Access

Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy

Morano, F., Corallo, S., Lonardi, S., Raimondi, A., Cremolini, C., Rimassa, L., Murialdo, R., Zaniboni, A., Sartore-Bianchi, A., Tomasello, G., Racca, P., Clavarezza, M., Adamo, V., Perrone, F., Gloghini, A., Tamborini, E., Busico, A., Martinetti, A., Palermo, F., Loupakis, F. & 5 others, Milione, M., Fucà, G., Di Bartolomeo, M., de Braud, F. & Pietrantonio, F., Nov 20 2019, In : Journal of Clinical Oncology. 37, 33, p. 3099-3110 12 p.

Research output: Contribution to journalArticle

Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy

Morano, F., Corallo, S., Lonardi, S., Raimondi, A., Cremolini, C., Rimassa, L., Murialdo, R., Zaniboni, A., Sartore-Bianchi, A., Tomasello, G., Racca, P., Clavarezza, M., Adamo, V., Perrone, F., Gloghini, A., Tamborini, E., Busico, A., Martinetti, A., Palermo, F., Loupakis, F. & 5 others, Milione, M., Fucà, G., Di Bartolomeo, M., de Braud, F. & Pietrantonio, F., Nov 20 2019, In : Journal of Clinical Oncology. 37, 33, p. 3099-3110 12 p.

Research output: Contribution to journalArticle

Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study

Cosimo, S. D., Verde, N. L., Moretti, A., Cazzaniga, M. E., Generali, D., Bianchi, G. V., Mariani, L., Torri, V., Crippa, F., Paolini, B., Scaperrotta, G., De Santis, M. C., Nicola, M. D., Apolone, G., Gulino, A., Tripodo, C., Colombo, M. P., Folli, S. & de Braud, F., Jan 1 2019, In : PLoS One. 14, 8, e0220644.

Research output: Contribution to journalArticle

Open Access

Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results

Sharma, P., Siefker-Radtke, A., de Braud, F., Basso, U., Calvo, E., Bono, P., Morse, M. A., Ascierto, P. A., Lopez-Martin, J., Brossart, P., Rohrberg, K., Mellado, B., Fischer, B. S., Meadows-Shropshire, S., Abdel Saci, Callahan, M. K. & Rosenberg, J., Jul 1 2019, In : Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 37, 19, p. 1608-1616 9 p.

Research output: Contribution to journalArticle

Nivolumab alone and with ipilimumab in previously treated metastatic urothelial carcinoma: CheckMate 032 nivolumab 1 mg/kg plus ipilimumab 3 mg/kg expansion cohort results

Sharma, P., Siefker-Radtke, A., de Braud, F., Basso, U., Calvo, E., Bono, P., Morse, M. A., Ascierto, P. A., Lopez-Martin, J., Brossart, P., Rohrberg, K., Mellado, B., Fischer, B. S., Meadows-Shropshire, S., Saci, A., Callahan, M. K. & Rosenberg, J., 2019, In : Journal of Clinical Oncology. 37, 19, p. 1608-1616 9 p.

Research output: Contribution to journalArticle

Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial

Platania, M., Pasini, F., Porcu, L., Boeri, M., Verderame, F., Modena, Y., Del Conte, A., Nichetti, F., Garassino, M. C., Martinetti, A., Sottotetti, E., Cavanna, L., Vattemi, E., Pozzessere, D., Bertolini, A., Irtelli, L., Verri, C., Sozzi, G., Proto, C., Pastorino, U. & 12 others, Torri, V., Fraccon, A. P., Spinnato, F., Signorelli, D., Lo Russo, G., Tuzi, A., Gallucci, R., Cinieri, S., Mencoboni, M., Antonelli, P., Giacomelli, L. & de Braud, F., Jun 2019, In : Lung Cancer. 132, p. 17-23 7 p.

Research output: Contribution to journalArticle

Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials

Modest, D. P., Rivera, F., Bachet, J. B., de Braud, F., Pietrantonio, F., Koukakis, R., Demonty, G. & Douillard, J. Y., Jul 15 2019, In : International Journal of Cancer. 145, 2, p. 576-585 10 p.

Research output: Contribution to journalArticle

Open Access